The NIH is offering the Director 27s New Innovator Award, aimed at supporting innovative research projects. Applications are due by August 17, 2026, under CFDA 93.310, making this a timely opportunity for early-career researchers.
Why it matters. This award encourages groundbreaking research, providing up to $1.5 million over five years to eligible applicants, including early-career scientists.
Our readExpect a competitive field as this funding supports high-risk, high-reward research initiatives.
Source · Grants.gov
The Administration for Community Living is accepting applications for the National Resource Centers on Older Indians, Alaska Natives, and Native Hawaiian Programs. The deadline is July 27, 2026, under CFDA 93.048, targeting community organizations serving these populations.
Why it matters. This funding opportunity supports culturally tailored services for Native elders, with an emphasis on improving health and wellness.
Our readThis is a crucial chance for organizations focused on Indigenous elder care to secure funding and expand their outreach.
Source · Grants.gov
The USDA has revised technical guidelines for agricultural biofuel feedstocks, impacting how producers report carbon intensity. This final rule updates previous guidelines established in January 2025.
Why it matters. The changes will affect agricultural producers involved in biofuel feedstock production, influencing compliance and reporting practices.
Our readProducers should prepare for new verification processes that could alter operational costs and reporting requirements.
Source · Federal Register
The FDA will hold a public meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee to discuss the Biologics License Application for Deramiocel from Capricor, Inc. This meeting is crucial for stakeholders in the regenerative medicine sector.
Why it matters. This meeting is crucial for stakeholders in the regenerative medicine sector.
Our readWatch for insights from the advisory committee that could influence regulatory strategies for gene therapy developers.
Source · Federal Register